NovoCure Limited (NVCR)

NovoCure Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Revenue	655.35	605.22	509.34	537.84
Revenue Growth (YoY)	8.28%	18.82%	-5.30%	-
Cost of Revenue	166.88	137.18	128.28	114.87
Gross Profit	488.47	468.04	381.06	422.97
Selling, General & Admin	417.73	428.89	390.87	306.41
Research & Development	224.54	209.65	223.06	206.09
Total Operating Expenses	642.27	638.54	613.93	512.5
Operating Income	-153.8	-170.5	-232.87	-89.52
Interest Expense	-17.55	-39.33	-41.13	-7.68
Total Non-Operating Income (Expense)	-17.55	-39.33	-41.13	-7.68
Pretax Income	-136.25	-131.16	-191.74	-81.85
Provision for Income Taxes	-0.02	37.47	15.3	10.69
Net Income	-136.23	-168.63	-207.04	-92.53
Net Income to Common	-136.23	-168.63	-207.04	-92.53
Shares Outstanding (Basic)	111	108	106	105
Shares Outstanding (Diluted)	111	108	106	105
Shares Change (YoY)	3.37%	1.36%	1.65%	-
EPS (Basic)	-1.22	-1.56	-1.95	-0.88
EPS (Diluted)	-1.22	-1.56	-1.95	-0.88
Shares Outstanding	112.49	108.52	107.08	105.05
Free Cash Flow	-75.68	-69.22	-100.43	9.43
Free Cash Flow Per Share	-0.68	-0.64	-0.94	0.09
Gross Margin	74.54%	77.33%	74.81%	78.64%
Operating Margin	-23.47%	-28.17%	-45.72%	-16.64%
Profit Margin	-20.79%	-27.86%	-40.65%	-17.20%
FCF Margin	-11.55%	-11.44%	-19.72%	1.75%
EBITDA	-139.15	-159.26	-221.9	-78.9
EBITDA Margin	-21.23%	-26.31%	-43.57%	-14.67%
EBIT	-153.8	-170.5	-232.87	-89.52
EBIT Margin	-23.47%	-28.17%	-45.72%	-16.64%
Effective Tax Rate	0.02%	-28.56%	-7.98%	-13.06%

Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q